Resistance to Anti-EGFR Therapies in Metastatic Colorectal Cancer: Underlying Mechanisms and Reversal Strategies

Overview

Journal J Exp Clin Cancer Res

Publisher Biomed Central

Specialty Oncology

Date 2021 Oct 19

PMID 34663410

Citations 73

Authors

Jing Zhou

Qing Ji

Qi Li

Affiliations

Soon will be listed here.

Abstract

Cetuximab and panitumumab are monoclonal antibodies (mAbs) against epidermal growth factor receptor (EGFR) that are effective agents for metastatic colorectal cancer (mCRC). Cetuximab can prolong survival by 8.2 months in RAS wild-type (WT) mCRC patients. Unfortunately, resistance to targeted therapy impairs clinical use and efficiency. The mechanisms of resistance refer to intrinsic and extrinsic alterations of tumours. Multiple therapeutic strategies have been investigated extensively to overcome resistance to anti-EGFR mAbs. The intrinsic mechanisms include EGFR ligand overexpression, EGFR alteration, RAS/RAF/PI3K gene mutations, ERBB2/MET/IGF-1R activation, metabolic remodelling, microsatellite instability and autophagy. For intrinsic mechanisms, therapies mainly cover the following: new EGFR-targeted inhibitors, a combination of multitargeted inhibitors, and metabolic regulators. In addition, new cytotoxic drugs and small molecule compounds increase the efficiency of cetuximab. Extrinsic alterations mainly disrupt the tumour microenvironment, specifically immune cells, cancer-associated fibroblasts (CAFs) and angiogenesis. The directions include the modification or activation of immune cells and suppression of CAFs and anti-VEGFR agents. In this review, we focus on the mechanisms of resistance to anti-EGFR monoclonal antibodies (anti-EGFR mAbs) and discuss diverse approaches to reverse resistance to this therapy in hopes of identifying more mCRC treatment possibilities.

Citing Articles

Negative Hyperselection in Metastatic Colorectal Cancer for First-Line Anti-EGFR Therapy: A Narrative Review.

Ciappina G, Toscano E, Ottaiano A, Capuozzo M, Consolo P, Maiorana E Int J Mol Sci. 2025; 26(5).

PMID: 40076838 PMC: 11900077. DOI: 10.3390/ijms26052216.

Preclinical evaluation of Cu-labeled cetuximab in immuno-PET for detecting sentinel lymph node metastasis in epidermal growth factor receptor-positive breast cancer.

Usui T, Miyake T, Watabe T, Kato H, Yoshii Y, Naka S Breast Cancer Res. 2025; 27(1):33.

PMID: 40055744 PMC: 11889786. DOI: 10.1186/s13058-025-01972-4.

A novel oncolytic vaccinia virus with multiple gene modifications involved in viral replication and maturation increases safety for intravenous administration while maintaining proliferative potential in cancer cells.

Okita G, Suenaga K, Sakaguchi M, Murakami T PLoS One. 2025; 20(3):e0312205.

PMID: 40048445 PMC: 11884718. DOI: 10.1371/journal.pone.0312205.

Genomic and micro-environmental insights into drug resistance in colorectal cancer liver metastases.

Kuang J, Li J, Zhou S, Li Y, Lin J, Huang W Discov Oncol. 2025; 16(1):241.

PMID: 40009285 PMC: 11865409. DOI: 10.1007/s12672-025-01976-8.

The Use of Plant Viral Nanoparticles in Cancer Biotherapy-A Review.

Komane M, Kayoka-Kabongo P, Rutkowska D Viruses. 2025; 17(2).

PMID: 40006973 PMC: 11860677. DOI: 10.3390/v17020218.

References

Rosa R, Melisi D, Damiano V, Bianco R, Garofalo S, Gelardi T . Toll-like receptor 9 agonist IMO cooperates with cetuximab in K-ras mutant colorectal and pancreatic cancers. Clin Cancer Res. 2011; 17(20):6531-41. DOI: 10.1158/1078-0432.CCR-10-3376. View

Cremolini C, Rossini D, DellAquila E, Lonardi S, Conca E, Del Re M . Rechallenge for Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer With Acquired Resistance to First-line Cetuximab and Irinotecan: A Phase 2 Single-Arm Clinical Trial. JAMA Oncol. 2018; 5(3):343-350. PMC: 6439839. DOI: 10.1001/jamaoncol.2018.5080. View

Wang J, Hsieh J, Chen F, Yeh C, Alexandersen K, Huang T . High frequency of activated K-ras codon 15 mutant in colorectal carcinomas from Taiwanese patients. Int J Cancer. 2003; 107(3):387-93. DOI: 10.1002/ijc.11417. View

Misale S, Bozic I, Tong J, Peraza-Penton A, Lallo A, Baldi F . Vertical suppression of the EGFR pathway prevents onset of resistance in colorectal cancers. Nat Commun. 2015; 6:8305. PMC: 4595628. DOI: 10.1038/ncomms9305. View

Parseghian C, Parikh N, Wu J, Jiang Z, Henderson L, Tian F . Dual Inhibition of EGFR and c-Src by Cetuximab and Dasatinib Combined with FOLFOX Chemotherapy in Patients with Metastatic Colorectal Cancer. Clin Cancer Res. 2017; 23(15):4146-4154. PMC: 5540760. DOI: 10.1158/1078-0432.CCR-16-3138. View

Schirripa M, Zhang W, Heinemann V, Cao S, Okazaki S, Yang D . Single nucleotide polymorphisms in the IGF-IRS pathway are associated with outcome in mCRC patients enrolled in the FIRE-3 trial. Int J Cancer. 2017; 141(2):383-392. PMC: 5510747. DOI: 10.1002/ijc.30715. View

Van Cutsem E, Huijberts S, Grothey A, Yaeger R, Cuyle P, Elez E . Binimetinib, Encorafenib, and Cetuximab Triplet Therapy for Patients With V600E-Mutant Metastatic Colorectal Cancer: Safety Lead-In Results From the Phase III BEACON Colorectal Cancer Study. J Clin Oncol. 2019; 37(17):1460-1469. PMC: 7370699. DOI: 10.1200/JCO.18.02459. View

Vincenzi B, Santini D, Russo A, Gavasci M, Battistoni F, Dicuonzo G . Circulating VEGF reduction, response and outcome in advanced colorectal cancer patients treated with cetuximab plus irinotecan. Pharmacogenomics. 2007; 8(4):319-27. DOI: 10.2217/14622416.8.4.319. View

Cappuzzo F, Varella-Garcia M, Finocchiaro G, Skokan M, Gajapathy S, Carnaghi C . Primary resistance to cetuximab therapy in EGFR FISH-positive colorectal cancer patients. Br J Cancer. 2008; 99(1):83-9. PMC: 2453041. DOI: 10.1038/sj.bjc.6604439. View

10.

Wang F, Fu X, Chen P, Wu P, Fan X, Li N . SPSB1-mediated HnRNP A1 ubiquitylation regulates alternative splicing and cell migration in EGF signaling. Cell Res. 2017; 27(4):540-558. PMC: 5385621. DOI: 10.1038/cr.2017.7. View

11.

Subbiah V, Khawaja M, Hong D, Amini B, Yungfang J, Liu H . First-in-human trial of multikinase VEGF inhibitor regorafenib and anti-EGFR antibody cetuximab in advanced cancer patients. JCI Insight. 2017; 2(8). PMC: 5396533. DOI: 10.1172/jci.insight.90380. View

12.

Lee H, Son E, Lee K, Lee Y, Kim Y, Lee J . Promising Therapeutic Efficacy of GC1118, an Anti-EGFR Antibody, against KRAS Mutation-Driven Colorectal Cancer Patient-Derived Xenografts. Int J Mol Sci. 2019; 20(23). PMC: 6928876. DOI: 10.3390/ijms20235894. View

13.

Arena S, Siravegna G, Mussolin B, Kearns J, Wolf B, Misale S . MM-151 overcomes acquired resistance to cetuximab and panitumumab in colorectal cancers harboring EGFR extracellular domain mutations. Sci Transl Med. 2016; 8(324):324ra14. DOI: 10.1126/scitranslmed.aad5640. View

14.

Jhawer M, Goel S, Wilson A, Montagna C, Ling Y, Byun D . PIK3CA mutation/PTEN expression status predicts response of colon cancer cells to the epidermal growth factor receptor inhibitor cetuximab. Cancer Res. 2008; 68(6):1953-61. PMC: 3972216. DOI: 10.1158/0008-5472.CAN-07-5659. View

15.

Duldulao M, Lee W, Nelson R, Li W, Chen Z, Kim J . Mutations in specific codons of the KRAS oncogene are associated with variable resistance to neoadjuvant chemoradiation therapy in patients with rectal adenocarcinoma. Ann Surg Oncol. 2013; 20(7):2166-71. PMC: 5584556. DOI: 10.1245/s10434-013-2910-0. View

16.

Bertotti A, Migliardi G, Galimi F, Sassi F, Torti D, Isella C . A molecularly annotated platform of patient-derived xenografts ("xenopatients") identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer. Cancer Discov. 2012; 1(6):508-23. DOI: 10.1158/2159-8290.CD-11-0109. View

17.

Bibeau F, Lopez-Crapez E, Di Fiore F, Thezenas S, Ychou M, Blanchard F . Impact of Fc{gamma}RIIa-Fc{gamma}RIIIa polymorphisms and KRAS mutations on the clinical outcome of patients with metastatic colorectal cancer treated with cetuximab plus irinotecan. J Clin Oncol. 2009; 27(7):1122-9. DOI: 10.1200/JCO.2008.18.0463. View

18.

Bardelli A, Siena S . Molecular mechanisms of resistance to cetuximab and panitumumab in colorectal cancer. J Clin Oncol. 2010; 28(7):1254-61. DOI: 10.1200/JCO.2009.24.6116. View

19.

Hong S, Kim S, Kim H, Kang M, Jang H, Lee W . Targeting the PI3K signaling pathway in KRAS mutant colon cancer. Cancer Med. 2015; 5(2):248-55. PMC: 4735771. DOI: 10.1002/cam4.591. View

20.

Price T, Ang A, Boedigheimer M, Kim T, Li J, Cascinu S . Frequency of S492R mutations in the epidermal growth factor receptor: analysis of plasma DNA from patients with metastatic colorectal cancer treated with panitumumab or cetuximab monotherapy. Cancer Biol Ther. 2020; 21(10):891-898. PMC: 7583702. DOI: 10.1080/15384047.2020.1798695. View